Interne link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets december 08, 2023 om 12:30 PM UTC
Interne link ProQR Announces Third Quarter 2023 Operating and Financial Results november 07, 2023 om 12:00 PM UTC
Interne link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing november 06, 2023 om 12:00 PM UTC
Interne link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference september 28, 2023 om 12:00 PM UTC
Interne link ProQR Therapeutics Provides Update on Ophthalmic Assets september 27, 2023 om 11:00 AM UTC
Interne link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference september 07, 2023 om 12:00 PM UTC
Interne link ProQR Announces Second Quarter 2023 Operating and Financial Results augustus 03, 2023 om 11:00 AM UTC
Interne link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets augustus 01, 2023 om 11:00 AM UTC
Interne link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit juli 06, 2023 om 11:00 AM UTC
Interne link ProQR Announces First Quarter 2023 Operating and Financial Results mei 16, 2023 om 11:00 AM UTC
Interne link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 mei 09, 2023 om 12:00 PM UTC
Interne link ProQR Announces Upcoming Investor Conferences in April and May april 20, 2023 om 12:00 PM UTC
Interne link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 april 18, 2023 om 12:00 PM UTC
Interne link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event maart 29, 2023 om 12:00 PM UTC
Interne link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing maart 14, 2023 om 12:00 PM UTC
Interne link ProQR to Present at Upcoming Scientific and Industry Conferences maart 07, 2023 om 01:00 PM UTC
Interne link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 februari 28, 2023 om 01:00 PM UTC
Interne link ProQR Announces Extraordinary General Meeting of Shareholders december 27, 2017 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa november 29, 2017 om 12:00 PM UTC
Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference november 21, 2017 om 12:00 PM UTC
Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares november 14, 2017 om 12:44 PM UTC
Interne link ProQR Announces Proposed Public Offering of Ordinary Shares november 13, 2017 om 09:01 PM UTC
Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness november 13, 2017 om 12:00 PM UTC
Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board november 09, 2017 om 12:00 PM UTC